161 related articles for article (PubMed ID: 10547195)
1. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
Mohammad RM; Li Y; Mohamed AN; Pettit GR; Adsay V; Vaitkevicius VK; Al-Katib AM; Sarkar FH
Pancreas; 1999 Nov; 19(4):353-61. PubMed ID: 10547195
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
Mohammad RM; Dugan MC; Mohamed AN; Almatchy VP; Flake TM; Dergham ST; Shields AF; Al-Katib AA; Vaitkevicius VK; Sarkar FH
Pancreas; 1998 Jan; 16(1):19-25. PubMed ID: 9436858
[TBL] [Abstract][Full Text] [Related]
3. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
Mohammad RM; Al-Katib A; Pettit GR; Vaitkevicius VK; Joshi U; Adsay V; Majumdar AP; Sarkar FH
Clin Cancer Res; 1998 Apr; 4(4):887-94. PubMed ID: 9563882
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.
Mohammad RM; Adsay NV; Philip PA; Pettit GR; Vaitkevicius VK; Sarkar FH
Anticancer Drugs; 2001 Oct; 12(9):735-40. PubMed ID: 11593055
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer.
He Z; Evelhoch JL; Mohammad RM; Adsay NV; Pettit GR; Vaitkevicius VK; Sarkar FH
Pancreas; 2000 Jul; 21(1):69-76. PubMed ID: 10881935
[TBL] [Abstract][Full Text] [Related]
9. Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine.
Li Y; Singh B; Ali N; Sarkar FH
Int J Mol Med; 1999 Jun; 3(6):647-53. PubMed ID: 10341297
[TBL] [Abstract][Full Text] [Related]
10. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
11. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E
Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869
[TBL] [Abstract][Full Text] [Related]
12. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Loukopoulos P; Kanetaka K; Takamura M; Shibata T; Sakamoto M; Hirohashi S
Pancreas; 2004 Oct; 29(3):193-203. PubMed ID: 15367885
[TBL] [Abstract][Full Text] [Related]
13. A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
Sorio C; Moore PS; Ennas MG; Tecchio C; Bonora A; Sartoris S; Balzarini P; Grigolato P; Scarpa A
Virchows Arch; 2004 Mar; 444(3):269-77. PubMed ID: 14677066
[TBL] [Abstract][Full Text] [Related]
14. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Réjiba S; Wack S; Aprahamian M; Hajri A
Cancer Sci; 2007 Jul; 98(7):1128-36. PubMed ID: 17489984
[TBL] [Abstract][Full Text] [Related]
15. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
17. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
19. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
Hasnis E; Alishekevitz D; Gingis-Veltski S; Bril R; Fremder E; Voloshin T; Raviv Z; Karban A; Shaked Y
Neoplasia; 2014 Jun; 16(6):501-10. PubMed ID: 24957319
[TBL] [Abstract][Full Text] [Related]
20. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
